EU and US could reach trade deal this weekend - Reuters
Bridgette P. Heller, a director at Dexcom Inc. (NASDAQ:DXCM), has sold 352 shares of the company’s common stock, according to a recent SEC filing. The transaction comes as InvestingPro data shows the stock trading significantly below its 52-week high of $142, having declined about 47% over the past year. Notably, while this director is selling, management has been actively buying back shares. The shares were sold at a price of $70.33 each, totaling $24,756. Following this transaction, Heller holds 22,997 shares, which include 2,618 unvested restricted stock units. These units are set to vest on the earlier of the one-year anniversary of their grant date or Dexcom’s 2025 Annual Meeting of Stockholders. The sale was conducted under a 10b5-1 Plan, which allows for the orderly disposition of shares. For comprehensive insider trading analysis and 14+ additional key insights about DXCM, InvestingPro subscribers can access the company’s detailed Pro Research Report.
In other recent news, DexCom reported fourth-quarter earnings that fell short of analyst expectations, with adjusted earnings per share at $0.45 compared to the anticipated $0.52. However, revenue for the quarter was slightly above expectations at $1.11 billion, representing an 8% year-over-year increase. For the full year 2024, the company’s revenue grew by 11% to $4.03 billion, with U.S. revenue up 10% and international revenue rising 15%. Looking ahead, DexCom has forecasted 2025 revenue of approximately $4.6 billion, which is slightly below the consensus of $4.61 billion.
In other developments, DexCom received a warning letter from the FDA related to manufacturing processes, but the company stated it does not expect this to impact its manufacturing capacity or financial projections. BTIG analysts maintained their Buy rating and $120 price target for DexCom shares despite the FDA letter. Additionally, Bernstein analysts raised their price target for DexCom shares to $100 from $89, citing a return to stability in the latter half of 2024.
Lastly, DexCom announced the addition of Renée Galá to its Board of Directors, bringing her extensive experience in financial and strategic leadership within the life sciences sector. Galá’s appointment is anticipated to contribute valuable insights as DexCom continues its growth efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.